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Abstract Discriminating patients with a low risk of progres-
sion from those with lethal prostate cancer is one of the main
challenges in prostate cancer management. Indeed, such dis-
crimination is essential if we aim to avoid overtreatment in
men with indolent disease and to improve survival in those
men with lethal disease. We are reporting on the current liter-
ature on such prognostic tools that are now available, their
clinical role and their limitations in individualizing care. There
is an urgent need to incorporate such genomic tools into new
platform-based clinical trial structures to further develop and
validate prognostic and predictive biomarkers and provide
prostate cancer patients with an effective and cost-efficient
access to new drugs in the setting of personalized treatment.
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Introduction
In Europe, over 417,000 men were diagnosed with prostate
cancer in 2012. Some patients will have highly aggressive
disease that might metastasize early and ultimately prove fatal.
In Europe, more than 90,000 men die of prostate cancer every
year, that is less than one out of five patients [1]. The majority
of the patients will have slow growing relatively harmless
tumors that will not threaten their health during lifetime and
can be appropriately managed with active surveillance or local
treatment. For those developing lethal disease, there has been
a major advance in treatment with the introduction of seven
systemic treatments in addition to androgen deprivation ther-
apy that has been the sole systemic treatment for the last
60 years. Unfortunately, their use has been constrained to pa-
tients who have failed local and hormonal treatment thus con-
ferring a very limited benefit of a few months. To increase
survival, it is crucial to move this drug earlier in the disease.
But the accurate risk stratification becomes compulsory to
avoid overtreatment of indolent disease and concentrate on
men with lethal tumors. Compared to diagnostic standards
applied in other cancers, the evaluation of prostate cancer
aggressiveness is still archaic. Initial evaluation and treatment
allocation are based exclusively on the combination of PSA
value, histological grading, and clinic-radiological TNM stag-
ing. In this context, many studies have focused on the molec-
ular basis of prostate cancer and highlighted several alterations
in well-characterized cancer pathways, the androgen/
androgen receptor (AR) signaling, gene fusions or mutations
directly related to gene expression, and chromatin regulation.
Promising genomic tools have been recently developed to
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predict an individual patient’s prognosis or response to sec-
ondary hormonal therapy. However, prostate cancer is a ge-
netically heterogeneous disease and despite the impressive
progress in cataloging genomic alterations in prostate cancer,
the prognostic significance of the majority of these changes
remains unclear and complicates risk stratification and selec-
tion of management strategies.
In this review, the focus is on currently available tissue-
based genomic markers, their role in daily clinical practice
and the needs for clinical trials to prove the value of these
markers in precision prostate cancer care.
Genetic Pathways in Prostate Cancer
Several genomic abnormalities were described in relation to
prostate cancer development and progression. The Catalogue
of Somatic Mutations in Cancer (COSMIC) database, an on-
line database of somatically acquired mutations found in hu-
man cancers, displays data from different tumors including
several hundreds of prostate cancer samples (http://cancer.
sanger.ac.uk/cosmic) [2]. Among the top 20 most frequently
altered genes in prostate cancer are several, well-known genes
involved in tumor development and progression. The most
frequently altered genes are TP53 (10 %), PTEN (8 %), SPOP
(7 %), KRAS (5 %), and EGFR (4 %), but the frequency of
these alterations—as indicated—is rather low and several oth-
er tumor driving genes have even lower incidence rates (i.e.,
FOXA1 3%, BRAF 2%, and PI3KCA 2%). Although TP53
and PTEN have been described in advanced disease and
poorer survival outcomes, it is not surprising that the
majority of these alterations lack independent prognostic
significance [3–7].
Another important mutation is represented by the
TMPRSS2-ERG gene fusion. This fusion is felt to be associ-
ated with the early onset of prostate cancer. Many studies have
been performed in order to test the association between
TMPRSS2-ERG fusion and outcomes, in particular after rad-
ical prostatectomy (RP) or after biopsy but most of have failed
to define a clinical significance of this fusion [8–12]. Subse-
quently, increased copy numbers of the fusion gene have been
associated with worse survival or allowed classification of the
cohort according to TMPRSS2-ERG fusion status and then
certain other markers demonstrated significance based on
whether fusion was present or absent [13]. ERG gene assays,
which measure the fusion of TMPRSS2 to ERG in prostate
cancer tissues, are underway. This tissue assay aims to identify
prostate cancer aggressiveness and may lead to personaliza-
tion of treatment options.
Moreover, recent reports demonstrated the role of different
micro-RNAs in prognostication outcome of high-risk prostate
cancer treated with RP [14–16]. Among these, miR-221 was
recently reported and externally validated as an independent
predictor of cancer-related death of high-risk prostate cancer
patients, by partially regulating JAK/STAT signaling pathway
and sensitizing prostate cancer cells to interferon-gamma
treatment [17•]. These analyses are standing out for several
reasons. First, the described single biomarker had a high pre-
diction of cancer-related death (area under the curve (AUC)
90.3 %). Second, these results were confirmed by an external
validation in an independent cohort. Third, the reported func-
tional analysis demonstrated the biological function of this
biomarker as a tumor suppressor regulating the JAK/STAT
signaling pathway and sensitization to interferon-gamma
treatment; thus, offering the chance for new treatment modal-
ities in the future.
In summary, a multitude of efforts have been undertaken to
identify genomic alterations associated with prostate cancer
metastasis and to predict an individual’s prognosis. But de-
spite these achievements, the prognostic significance of the
majority of molecular alterations described remains unclear.
The reasons are multiple and range from the patient cohorts
analyzed—which were often not well-annotated, or included
only low- and intermediate-risk patients with a long natural
history and limited risk for metastasis and prostate cancer
death—to probe sampling of a tumor in which tumor
multifocality and heterogeneity are known factors complicat-
ing biomarker research [18, 19]. Finally and most importantly,
the tests are often not validated in independent patient cohorts.
Decipher™
Decipher™ is a genomic test that was co-developed by
GenomeDx Biosciences (Vancouver, BC, Canada) and the
Mayo Clinic to assess the post RP risk of developing recur-
rence or metastatic disease of prostate cancer patients. This
test is based on the RNA expression of 22 genes involved in
cell adhesion, migration, tumor motility, immune system
modulation, cell cycle control, and some genes with unknown
or non-coding function. This test provides a percentage risk of
metastases at 5 years. Some retrospective studies have ana-
lyzed the ability of Decipher™ in predicting recurrence after
RP. Alshalafa et al. analyzed differences in patients that devel-
oped biochemical recurrence (BCR), clinical metastases, or
were free from any recurrence during follow up, finding that
Decipher™ can represent a useful tool predicting patients that
will develop clinical recurrence after BCR [20]. In this setting,
many other reports corroborate the ability of this test to predict
metastases after therapy with curative intent [21–25]. In a
similar context, Klein et al. reported on 162 patients with
higher risk prostate cancer including some patients with pos-
itive lymph nodes treated with RP without adjuvant therapies
and demonstrated an enhanced ability to predict which patient
developed metastases when compared to using routine
clinico-pathological parameters [25]. Den et al. focused on
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patients who underwent RP and were found with pT3 and/or
positive margins and received postoperative RT [26]. They
reported an AUC in predicting BCR and clinical recurrence
of 78 and 80 %, respectively. They concluded that a low ge-
nomic classifier score could represent an indicator for expec-
tant management with possibility of delayed RT, while pa-
tients with high genomic classifier score should be considered
for adjuvant RT. Only one report showed the ability of this test
in the prediction of cancer-specific mortality (CSM).
Cooperberg et al. described 185 surgically treated high-risk
prostate cancer patients and compared the Cancer of the Pros-
tate Risk Assessment score (CAPRA) and the Decipher geno-
mic classifier and were able to show an independent predic-
tion of CSM after RP and stronger association of the genomic
classifier over CAPRA in this prediction [27•]. This report is
of importance because it demonstrated the added value of this
test to a standard clinical classification system.
In summary, this test is a promising new tool to better risk
stratify prostate cancer patients after RP. One advantage of this
test is the fact that it was tested and validated to predict metastasis
and prostate cancer mortality after RP. How the results of this
genomic test should be used to guide an individual patient’s
treatment is unclear but there is suggestion of a predictive com-
ponent as to the receipt and timing of postoperative radiation
therapy. Prospective clinical trials are necessary to prove the
value of this promising test to guide patient treatment after radical
prostatectomy and should not only evaluate oncological outcome
but also the patient’s quality of life and health care resources.
OncotypeDX®
OncotypeDX® is a diagnostic test that has been developed by
Genomic Health (Redwood City, California). By analyzing the
expression of 17 genes (includes 5 housekeeping genes) on bi-
opsies, it has been shown to enhance the ability to predict adverse
pathology (upgrading and/or upstaging) at RP in patients diag-
nosed with NCCN very-low, low, and low-intermediate disease.
To date, two studies were published assessing the impact of
OncotypeDX® on clinical practice. Klein et al. reported the ini-
tial discovery and validation on 608 patients who underwent
biopsy and had final pathology (grade and stage) assessed by
RP [25]. Thus, they were able to describe the impact of
OncotypeDX® in predicting adverse pathology at RP. Cullen
et al. used a similar setting and analyzed the biopsies from 431
prostate cancer patients with similar NCCN risk criteria. They
confirmed the good results reported by Klein et al. to predict
adverse pathology at RP and BCR [28].
In summary, OncotypeDX is a new tool to predict adverse
pathology in patients with low- to intermediate-risk prostate
cancer. But up to now, only one series reported data on pa-
tient’s outcome in terms of biochemical recurrence. Future
analysis including survival endpoints are necessary to prove
if the OncotypeDX test is helpful to better guide patients for
active surveillance or active treatment. However, the main
challenges in establishing this test in daily clinical practice
will be the endpoint used. It is well known that patients with
very low- to low/intermediate-risk prostate cancer have a long
natural history with a very low risk of metastasis even without
any treatment. So what does it mean for a prostate cancer
patient if his tumor is upgraded from a small Gleason score
3+3=6 tumor to a small 3+4=7 tumor? Does such an
upgrading really change the prognosis? Therefore, care has
to be taken when active treatment is recommended which is
based on a genomic test using surrogate endpoints instead of
survival endpoints. However, it appears most useful in the
patient and with the provider when contemplating active sur-
veillance and more information is needed. How this test im-
proves such risk stratification vs. multiparametric MRI is not
known or if it is complimentary or not to a MRI.
Prolaris®
Prolaris® is a diagnostic test that has been developed byMyriad
Genetics (Wakara Way, Salt Lake City, UT). This test is based
on evaluation of the expression of 31 cell cycle progression
genes and 15 housekeeping genes. It was designed to evaluate
patients with low-risk prostate cancer who may be candidates
for active surveillance as well as patients who are at high risk
for metastasis and who may benefit from closer monitoring or
additional therapy after curative intended treatment.
Cuzick et al. investigated 349 prostate biopsies evaluating
the impact of the cell cycle progression (CCP) score based on
the Prolaris® platform on outcomes [29]. Bishoff et al. ana-
lyzed 582 patients fromMartini Clinic (n=283), Durham Vet-
erans Affairs Medical Center (n=176), and Intermountain
Healthcare (n=123) and results showed that the CCP score
derived from biopsy samples was associated with adverse out-
comes after RP [27•]. Cuzick et al. evaluated the CCP score in
a subsequent study in two different cohorts of patients. One
cohort was treated with RP in the US and the other cohort was
treated conservatively or with TUR-P in the United Kingdom.
Both studies demonstrated the ability to predict the outcome
of the patients, but the endpoint used was different. For the RP
cohort, BCR was used and for the conservatively treated UK
group of patients’ time-to-death was the endpoint [30].
Cooperberg et al. externally validated the initial results of
the RP cohort published by Cuzick et al. in an independent
group of 413 patients and confirmed the ability of the CCP
score to predict BCR after RP. In addition, they found that
combining the CCP score and the CAPRA score improved
the concordance index for both the overall cohort and a low-
risk subset [31]. Freedland et al. demonstrated the value of the
CCP score to predict the outcome of patients treated with
primary radiation therapy [32].
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The test is commercialized now in several countries and
one of the main questions is what to do with the results of this
test. Crawford and coworkers pointed this out in an interesting
study analyzing how the results of the CCP score test affected
the recommendations for prostate cancer treatment. Physi-
cians reported changes of the intended treatment in 65 % of
the cases based on the results of the CCP score [33]. These led
to a 49.5 % reduction in surgical interventions and a 29.6 %
reduction in radiation therapy. They concluded that based on
responses of ordering physicians, the CCP report adds mean-
ingful new information to risk assessment for localized pros-
tate cancer patients. Test results led to changes in treatment
with reductions but also increases in interventional treatment
that were directionally aligned with prostate cancer risk spec-
ified by the test. Although it changed management strategies
in the majority of cases, it does not answer the question as to
whether it was a Bright^ decision to change and what exact
ramifications happen as the course changed perhaps compared
to a similar group where the test was not used.
In summary, the CCP score is a promising new tool to better
stratify prostate cancer patients. One of the limitations of this
tool is the use of biochemical recurrence as an endpoint in most
of the studies. What does the prediction of such an endpoint
mean for an individual patient? This may differ significantly. A
patient with an early PSA recurrence within 1 year after RP
with a short PSA-doubling time below 3 months obviously is
at the highest risk for progression and most uro-oncologists
will agree that this patient benefits from additional treatment.
But another patient with a PSA recurrence of 7 years after RP
with a PSA doubling time of 18 months has a completely
different prognosis, and treatment can be effectively initiated
at the time point of recurrence avoiding long-term treatment
side effects. The CCP score evaluation should focus more on
hard clinical endpoints. Unfortunately, only two studies report-
ed on survival endpoints. Further prospective clinical trials are
necessary in the future to prove this test as a prognostic bio-
marker and a tool to guide treatment. Although a registry-
based study demonstrated a significant rate of changes in treat-
ment recommendations the results of the CCP score should be
handled carefully until prospective clinical trials demonstrated
that these changes really translate into patient benefit.
Current Main Challenges for Biomarker and Drug
Development in Prostate Cancer
Impressive progress has been made in cataloging genomic alter-
ations in prostate cancer and the development of new prognostic
tools. Despite these achievements, the prognostic significance of
themajority of themolecular alterations and how these can guide
an individual patient’s treatment remains unclear. This is mainly
the result of the specific challenges in prostate cancer to estab-
lishing these relationships: long natural history, necessity for
long-term follow-up and large, well annotated cohorts, issues
of sampling and tumor multifocality and difficulties in defining
and understanding indolent lesions versus driver lesions associ-
ated with metastasis and mortality [18]. The clinical and the
molecular heterogeneity of prostate cancer complicate accurate
risk stratification and selection of management strategies [19].
However, molecular classification can allow the definition
of specific prostate cancer subclasses associated with distinct
patterns of genomic abnormalities. Genomic, transcriptomic,
and metabolomic analyses reveal that prostate cancer can be
sub-classified based on gene expression and single copy num-
ber alterations, with some success in predicting aggressive
features of disease or impact on prognosis [34–36]. Systemat-
ic sequencing studies continue to add data allowing the defi-
nition of molecular subclasses based on mutations and copy
number alterations. These discoveries raise the opportunity
that prostate cancer might soon transition from a poorly un-
derstood, clinically heterogeneous disease to a collection of
homogeneous subtypes identifiable by molecular criteria, as-
sociated with specific alterations, with distinct effects on pa-
tient prognosis, amenable to specific management strategies,
and perhaps vulnerable to more effective targeted therapies
[37•, 38•]. These reports are important because they demon-
strated tumor heterogeneity in homogeneous groups of pa-
tients with localized intermediate risk PCa and metastatic
castration-resistant PCa underlining the urgent need of a more
tailored, individualized treatment in these patients.
One of the main challenges in prostate cancer management
is how to translate the information gained from prognostic
tools and molecular sub-stratification information into clinical
practice. Widely metastatic prostate cancer is still a lethal dis-
ease and despite some survival gains by adding chemotherapy
at an earlier stage of the disease, secondary hormonal treat-
ment, or immunological manipulation, survival time of meta-
static patients is still limited [39–43]. A multitude of new
targeted drugs have been developed over the last decade,
and many of these drugs were tested in prostate cancer. Un-
fortunately, the majority of the phase III drug trials testing
such drugs were negative [44–49]. But are these targeted
drugs really not effective in prostate cancer? Or was the trial
design just too optimistic in believing that a Bone treatment fits
all^ approach would be successful in prostate cancer? Com-
plex and sophisticated clinical trial designs documenting bio-
logical mechanisms of action will be needed in the future. One
possible solution are collaborative molecular screening plat-
forms in which patients with specific genotypes are rapidly
identified and efficiently sorted to be included in sub-group
biomarker driven clinical trials. Such screening platforms are
allowing integrated drug/biomarker/drug development solu-
tions, cross validation, and benchmarking of technologies
alongside strict quality assurance/quality control criteria.
Providing efficient access for patients to molecularly driv-
en clinical trials is one of the aims of the Screening Patients for
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Efficient Clinical Trial Access (SPECTA) initiative developed
by the European Organisation for Research and Treatment of
Cancer (EORTC) [50•]. This report is of importance because it
described how new disease-oriented screening platforms can
optimize drug access, personalized medicine, and health-care
delivery. Such platforms are currently under development for
colorectal, lung, melanoma, brain, and prostate cancer within
the EORTC network.
Conclusion
Prostate cancer is a clinically and molecularly heterogeneous
disease. Discriminating patients with low risk of progression
from those with lethal prostate cancer is mandatory to avoid
overtreatment on the one side and to improve survival on the
other side. Some new promising prognostic tools are now
commercially available but their clinical role in individualiz-
ing care is still unclear. New, platform-based clinical trial
structures are urgently needed to develop and validate prog-
nostic and predictive biomarkers and provide prostate cancer
patients with an effective and cost-efficient access to new
drugs in the setting of personalized treatment.
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